L-Carnitine and NAFLD (Non-alcoholic fatty liver disease)

Non-alcoholic fatty liver disease (NAFLD) is a common condition among fitness enthusiasts, particularly those with diets high in fats.

Recent studies have highlighted the potential of L-carnitine in managing NAFLD. This post reviews a systematic review and meta-analysis that explores L-carnitine's efficacy and safety in treating NAFLD.

Study Overview

A systematic review and meta-analysis published in Systematic Reviews included eight randomized controlled trials (RCTs) involving 544 participants. The studies evaluated L-carnitine's effects on liver function and lipid profiles in NAFLD patients.

Key Findings

• Improved Liver Function: L-carnitine supplementation significantly improved liver enzyme levels (AST, ALT, γ-GT), indicating better liver function.
• Enhanced Lipid Profiles: Participants showed improvements in lipid profiles, including increased HDL cholesterol and reduced LDL cholesterol and triglycerides.
• Dosage and Duration: Effective dosages ranged from 1000 mg to 2000 mg per day, with treatment durations of 12 to 24 weeks showing the most benefits.

Safety and Side Effects

L-carnitine was well-tolerated among participants, with few reported side effects. The most common side effects were mild gastrointestinal issues.

Conclusion

L-carnitine shows promise in managing NAFLD by improving liver function and lipid profiles. Its safe and effective use can be a beneficial addition for those struggling with fatty liver conditions. For more details, refer to the full study here.